Incretin Atlas › Trials › MOMENTUM
MOMENTUM
Pemvidutide · obesity
Design
- Molecule(s)
- Pemvidutide
- Population
- obesity
- Phase
- 2
- Participants
- 391
- Duration
- 48 weeks
- Registry
- NCT05295875
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pemvidutide 2.4 mg | obesity | 48 | 391 | — | —−15.6 % vs −2.2 % estimand not specified | — | 19.6 vs 6.2 | — | 51.5 vs 11.3 | 27.8 vs 3.1 | — | −4.6 vs +3.5 | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (5)
- pemvidutide 2.4 mg · ae_dc · Summary of Safety and Tolerability table: Placebo (N=97) | 1
All AEs leading to discontinuation N (%) | 6 (6.2%) | 5 (5.1%) | 19 (19.2%) | 19 (19.6%)
- pemvidutide 2.4 mg · nausea · Summary of Safety and Tolerability table: Placebo (N=97) | 1
Nausea N (%) | 11 (11.3%) | 25 (25.5%) | 59 (59.6%) | 50 (51.5%)
- pemvidutide 2.4 mg · vomiting · Summary of Safety and Tolerability table: Placebo (N=97) | 1
Vomiting N (%) | 3 (3.1%) | 6 (6.1%) | 27 (27.3%) | 27 (27.8%)
- pemvidutide 2.4 mg · sbp · Blood Pressure and Heart Rate table
Blood Pressure and Heart Rate | Placebo (N=97) | 1.2 mg (N=98) | 1.8 mg (N=99) | 2.4 mg (N=97) Δ Systolic BP mm Hg, LSM (SE) | +3.5 (2.3) | -2.3 (2.2) | -1.6 (2.2) | -4.6 (2.3)
- pemvidutide 2.4 mg · weight_unsp · Summary of Efficacy Findings
Primary Endpoint: Body weight | Placebo (N=97) | 1.2 mg (N=98) | 1.8 mg (N=99) | 2.4 mg (N=97) Δ Body weight, all subjects, %, LSM (SE) [1 MMRM] | -2.2 (1.4) | -10.3 (1.4)*** | -11.2 (1.4)*** | -15.6 (1.4)***
Primary sources
- Altimmune, Inc.. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial). ClinicalTrials.gov identifier NCT05295875. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05295875
- Altimmune, Inc. Altimmune announces positive topline results from MOMENTUM 48-week phase 2 obesity trial of pemvidutide [press release, Form 8-K Exhibit 99.1]. Gaithersburg (MD): Altimmune; 2023 Nov 30. Available from: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/alt-20231130xex99d1.htm. Available from: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/alt-20231130xex99d1.htm
How to cite this page
Medical Adviser's Group. Incretin Atlas: MOMENTUM. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/momentum/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.